Journey Medical price to book ratio DERM
Market value divided by the book value of the company's net assets, since 2022.
- Today, Nov 2, 2026
- 4.2×
- 5-year median
- 5.7×
- Against its 5-year history
- 33rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.8× to 12.0×
- Peer median
- 1.5×
Journey Medical's price to book ratio is 4.2× as of Nov 2, 2026.
That is below its 5-year median of 5.7×, lower than on 67% of days in the last 5 years.
Over that time it ranged from 0.8× in Dec 2022 to 12.0× in Oct 2024.
The median for 10 large drugmakers of a similar size is 1.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.2× | 3.9× | 9.1× |
| 2025 | 8.3× | 6.9× | 11.5× |
| 2024 | 8.0× | 3.3× | 12.0× |
| 2023 | 6.1× | 0.9× | 8.5× |
| 2022 | 1.3× | 0.8× | 2.1× |
Against its peers
Companies in Drug Manufacturers - General nearest Journey Medical's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| DERMJourney Medical | 4.2× |
| NATRNatures Sunshine Products | 1.2× |
| LFVNLifevantage | 2.2× |
| SPROSpero Therapeutics | 1.4× |
| ATNMActinium Pharmaceuticals | 1.5× |
| CRMDCorMedix | 0.9× |
| ARVNArvinas | 0.9× |
| PBYIPuma Biotechnology | 3.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.8× |
| COLLCollegium Pharmaceutical | 2.5× |
| Peer median | 1.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Journey Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.